Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review

Fig. 1

Images of 123I-BMIPP myocardial scintigraphy. 123I-β-methyl-P-iodophenyl-pentadecanoic acid (BMIPP) cardiac scintigraphy obtained after 42 courses of pegylated liposomal doxorubicin showed no reduction of 123I- BMIPP uptake. (a) Early phase (30 min after intravenous injection); (b) Delayed phase (4 h after intravenous injection)

Back to article page